NCT04322630 is a clinical trial of Change in Soluble MER Concentration in Myocardial Inflammation, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Who is sponsoring NCT04322630?

NCT04322630 is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

What drugs are being tested in NCT04322630?

Interventions in NCT04322630: Change in Soluble MER Concentration.

What condition does NCT04322630 study?

NCT04322630 studies Myocardial Inflammation, Myocardial Infarction.

Is NCT04322630 still recruiting?

NCT04322630 is currently completed. Last updated 12 August 2021.

Last reviewed 2021-08-12 · How we verify

NCT04322630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mer-TK in Human Cardiac Cells

Completed Last updated 12 August 2021

What this trial tests

trial testing Change in Soluble MER Concentration in Myocardial Inflammation in 50 participants. Completed in 31 December 2020.

Timeline

10 May 2019

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Ann & Robert H Lurie Children's Hospital of Chicago
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	10 May 2019
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across United States

Drugs / interventions tested

Change in Soluble MER Concentration

Conditions studied

Myocardial Inflammation — all drugs for Myocardial Inflammation →
Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Who can join

Under 19, any sex, with Myocardial Inflammation or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The relationship between the immune system and the myocardium after myocardial ischemia is an evolving field of research. Crosstalk occurs between macrophages and cardiac myocytes to promote cardio-protection and resolution of inflammation after myocardial ischemia and reperfusion injury (MI/R injury). Myeloid-epithelial-reproductive tyrosine kinase (MerTK), a member of the TAM family of tyrosine kinase receptors (Tyro-Axl-MerTK), is a macrophage receptor that mediates efferocytosis, anti-inflammatory signaling, and resolution of inflammation. After MI/R injury, intact MerTK is necessary for the phagocytosis of dead cardiac myocytes and to promote anti-inflammatory signaling. Proteolytic cleavage of MerTK to its inactive form, soluble MER, restricts the capacity of macrophages to phagocytize dead cardiac myocytes and impairs MerTK-dependent anti-inflammatory signaling resulting in suppressive effects on cardiac remodeling and function. The Thorp lab at Northwestern University has previously measured soluble MER levels in both adult mice and humans and found that soluble MER concentrations increase after MI/R injury. In adult MI patients, soluble MER was measured post coronary artery reperfusion and was found to be increased (average 3200 pg/mL compared to 1700 pg/mL) compared to controls with stable cardiovascular disease. Based on murine data, the lab further postulated that reperfusion injury may directly interfere with MerTK-dependent cardiac repair as reactive oxygen species formed during reperfusion injury induce proteolytic cleavage of MerTK to soluble MER. Myocardial infarctions are rare events in pediatric patients. However, pediatric hearts are exposed to periods of hypoperfusion, ischemia, and inflammation during times of stress such as cardiac bypass and critical illness, and it is unknown how soluble MER levels change in response to these events. Thus, I was interested in investigating how soluble MER levels change after MI/R injury induced by cardiac bypass as well as in the utility of soluble MER as a biomarker of cardiac inflammation and injury in pediatric patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myocardial Inflammation

Currently open trials in the same condition.

NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting

Other Ann & Robert H Lurie Children's Hospital of Chicago trials

Trials by the same sponsor.

NCT07411300 — Supporting Caregivers Following Mental Health Emergency Department Visits · NA · recruiting
NCT06986148 — Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP) · NA · recruiting
NCT07372898 — Impact of Hospital to Home: Optimizing Preterm Infant Environment for Surgical Neonates and Their Parents (H-HOPE) · NA · recruiting
NCT07216326 — Our Voices Matter: Intervention for Depression in Youth · NA · recruiting
NCT06689943 — Pain After Strabismus Surgery · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04322630 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ann & Robert H Lurie Children's Hospital of Chicago
Last refreshed: 12 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing